8-K: INVO Bioscience and NAYA Biosciences Amend Merger Agreement, Extend Deadline to June 30

INVO Bioscience and NAYA Biosciences have amended their merger agreement, extending the deadline to June 30, 2024, and modifying the terms of an interim financing plan.

Summary

• INVO Bioscience and NAYA Biosciences have agreed to a third amendment to their merger agreement, extending the deadline for the merger to June 30, 2024.
• The amendment also modifies the definition of an 'Interim PIPE' to include two phases of financing.
• Phase 1 involves the sale of INVO's Series A Preferred Stock under a previous agreement.
• Phase 2 includes a private offering of INVO's preferred stock at $5.00 per share, aimed at supporting the company's fertility business and covering past payables.
• The company is free to secure additional funding from third parties without NAYA's consent.
• NAYA is scheduled to purchase the remaining 838,800 shares of INVO's Series A Preferred Stock in installments between May 10 and July 5, 2024, at $5.00 per share.
• INVO can terminate the merger agreement if NAYA breaches its obligations under the Securities Purchase Agreement.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the merger is still progressing, the need for a third amendment and the reliance on a private offering introduce some uncertainty. The extension provides more time, but also suggests potential challenges.

Positives

• The extension of the merger deadline provides more time for the deal to be completed.
• The modified 'Interim PIPE' structure provides a clear path for INVO to secure necessary funding.
• INVO's ability to seek additional funding independently offers flexibility.
• The scheduled purchases of Series A Preferred Stock by NAYA provide a predictable cash inflow for INVO.

Negatives

• The need for a third amendment to the merger agreement may indicate underlying issues or complexities.
• The reliance on a private offering for Phase 2 of the 'Interim PIPE' may introduce uncertainty.
• The potential for INVO to terminate the agreement if NAYA breaches the Securities Purchase Agreement highlights a risk of deal failure.

Risks

• The merger could still be terminated if NAYA breaches the Securities Purchase Agreement.
• The private offering for Phase 2 of the 'Interim PIPE' may not be fully subscribed.
• The company's ability to secure additional funding from third parties is not guaranteed.
• The merger may not be completed by the new deadline of June 30, 2024.

Future Outlook

The merger is expected to close by June 30, 2024, pending the successful completion of the Interim PIPE financing and other closing conditions.

Management Comments

• The parties agreed to extend the merger end date to June 30, 2024.
• The parties agreed to modify the definition of an Interim PIPE to include two phases of financing.
• The company remains free to secure any amount of funding from third parties on any terms the company deems reasonably acceptable under SEC and Nasdaq regulations without the prior written consent of NAYA.

Industry Context

This announcement reflects the ongoing consolidation and financing activities within the biotechnology and healthcare sectors, particularly in the fertility treatment space. Companies often seek mergers and acquisitions to expand their market presence and access capital.

Comparison to Industry Standards

• Merger extensions are not uncommon in complex deals, especially when financing is involved, similar to other biotech mergers that have faced delays.
• The use of a PIPE (Private Investment in Public Equity) structure for interim financing is a standard practice in the biotech industry, often used to bridge funding gaps before a merger.
• The valuation of preferred stock at $5.00 per share is within the typical range for private placements in similar companies, although the specific terms and conditions can vary widely.
• The staged purchase of shares by NAYA is a common approach to manage cash flow and risk in such transactions, similar to other staged investments in the biotech sector.

Stakeholder Impact

• Shareholders may experience uncertainty due to the merger extension and financing changes.
• Employees may be affected by the potential merger and any resulting organizational changes.
• Customers may experience changes in service or product offerings post-merger.
• Suppliers and creditors may be impacted by the financial restructuring and merger.

Next Steps

• NAYA will purchase the remaining 838,800 shares of INVO's Series A Preferred Stock according to the schedule.
• INVO will complete Phase 2 of the Interim PIPE financing.
• The parties will work towards closing the merger by June 30, 2024.

Key Dates

Keywords

merger, INVO Bioscience, NAYA Biosciences, Interim PIPE, Series A Preferred Stock, funding, private offering, Securities Purchase Agreement, amendment, fertility business